Cumberland Pharmaceuticals Stock Today
| CPIX Stock | USD 4.59 0.29 5.94% |
PerformanceGood
| Odds Of DistressAverage
|
Cumberland Pharmaceuticals is trading at 4.59 as of the 24th of March 2025; that is 5.94 percent decrease since the beginning of the trading day. The stock's open price was 4.88. Cumberland Pharmaceuticals has 51 percent odds of going through some form of financial distress in the next two years but had a very good returns during the last 90 days. The performance scores are derived for the period starting the 24th of December 2024 and ending today, the 24th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 11th of August 2009 | Category Healthcare | Classification Health Care |
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company has 13.97 M outstanding shares of which 500.7 K shares are currently shorted by private and institutional investors with about 0.08 trading days to cover. More on Cumberland Pharmaceuticals
Moving together with Cumberland Stock
Moving against Cumberland Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Cumberland Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Thematic Ideas | (View all Themes) | ||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Management, Drugs, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsCumberland Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Cumberland Pharmaceuticals' financial leverage. It provides some insight into what part of Cumberland Pharmaceuticals' total assets is financed by creditors.
| |||||
Cumberland Pharmaceuticals (CPIX) is traded on NASDAQ Exchange in USA. It is located in 1600 West End Avenue, Nashville, TN, United States, 37203 and employs 91 people. Cumberland Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 64.11 M. Cumberland Pharmaceuticals conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 13.97 M outstanding shares of which 500.7 K shares are currently shorted by private and institutional investors with about 0.08 trading days to cover.
Cumberland Pharmaceuticals currently holds about 18.22 M in cash with (612.19 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.24.
Check Cumberland Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Cumberland Pharmaceuticals is $64.11 Million. Cumberland Pharmaceuticals retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Cumberland Ownership Details
Cumberland Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Ubs Group Ag | 2024-12-31 | 8.2 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 2.7 K | |
| Tower Research Capital Llc | 2024-12-31 | 2.2 K | |
| Capital Advisors, Ltd. Llc | 2024-12-31 | 437 | |
| Wells Fargo & Co | 2024-12-31 | 250 | |
| Bank Of America Corp | 2024-12-31 | 65.0 | |
| Jpmorgan Chase & Co | 2024-12-31 | 19.0 | |
| Huntington National Bank | 2024-12-31 | 1.0 | |
| Schonfeld Strategic Advisors Llc | 2024-12-31 | 0.0 | |
| Renaissance Technologies Corp | 2024-12-31 | 507.2 K | |
| Vanguard Group Inc | 2024-12-31 | 374.3 K |
Cumberland Pharmaceuticals Historical Income Statement
Cumberland Stock Against Markets
Cumberland Pharmaceuticals Corporate Management
| James Herman | Chief Compliance Officer and VP of National Accounts | Profile | |
| John Hamm | Chief Officer | Profile | |
| Christophe Bitterman | Vice Marketing | Profile | |
| Todd Anthony | Vice Development | Profile | |
| Adam Mostafa | Managing Relations | Profile | |
| Erin Gull | Senior Associate | Profile |
Additional Tools for Cumberland Stock Analysis
When running Cumberland Pharmaceuticals' price analysis, check to measure Cumberland Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cumberland Pharmaceuticals is operating at the current time. Most of Cumberland Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cumberland Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cumberland Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cumberland Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.